Thilo Schroeder

Thilo Schroeder is a Managing Partner at Nextech Invest Ltd., where he directs early-stage venture capital investments in oncology and precision medicines. Before joining the investment firm in 2012, he developed Designed Ankyrin Repeat Proteins as protein inhibitors, a proprietary technology that was subsequently licensed to external partners. He also gained molecular biology expertise during his academic studies in Australia and an internship at Micromet, a biotechnology company later acquired by Amgen. Schroeder currently serves on the board of directors for Revolution Medicines and holds board observer roles at several other private portfolio companies. Over his career, he has allocated capital into numerous publicly traded therapeutic developers, acting as an early venture investor in Blueprint Medicines and IDEAYA Bioscience. His current professional focus centers on identifying first-in-class and best-in-class targeted cancer therapies across multiple drug modalities.